Trevi Therapeutics, Inc. (TRVI) is a clinical stage biopharmaceutical company which specializes in developing and commercializing innovative therapies for patients with serious or life-threatening diseases. The company is publicly listed and traded under the symbol "TRVI" on Nasdaq.
Founded in 2011, and based in New Haven, Connecticut, Trevi Therapeutics has dedicated its resources to unmet medical needs and has been working to provide revolutionary treatments for patients suffering from chronic pruritus and chronic cough. Chronic pruritus, or severe itching, and chronic cough are conditions that can significantly affect the quality of life, and at present, there are limited treatment options available.
Trevi Therapeutics' leading pipeline product is Haduvio™ (Nalbuphine ER), an extended-release oral tablet that targets a specific opioid receptor thought to reduce pruritus (itching) and cough. Haduvio is studied in several large patient populations, including Prurigo Nodularis (PN), chronic cough in Idiopathic Pulmonary Fibrosis (IPF), and chronic pruritus in Chronic Kidney Disease (CKD-aP).
Since its inception, Trevi has shown strong commitment to research and development. With top-notch scientists and researchers, the company undergoes stringent research methodologies and clinical trials to ensure the development of safe and effective treatments. In addition to the development of Haduvio, Trevi Therapeutics is also conducting preclinical studies on other drug candidates that target different pathologies.
Trevi's research approach and commitment to patient well-being have earned it recognition in the biotech sector. However, like all biotechnology companies, Trevi Therapeutics faces challenges in drug development, including regulatory hurdles, high development costs, and long lead times for drug approval and commercialization.
In its journey of over a decade, Trevi Therapeutics has evolved while undertaking significant efforts to contribute to the greater good of the medical community. The persistent dedication to developing novel treatments showcases the company’s goal of helping patients achieve a better quality of life, offering hope for those with otherwise limited options. Trevi continues to make strides in innovating new treatments, guided by its deep-seated commitment to making a positive impact on public health. In the coming years, the biopharmaceutical firm is poised to further its research and advance its development programs, aspiring to create medicines that truly make a difference in patients’ lives.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Trevi Therapeutics (TRVI) is a clinical-stage biopharmaceutical company focused on treating chronic cough in IPF and other lung diseases, presenting a compelling investment opportunity. The company's flagship product, Haduvio, is in advanced clinical trials, with analysts projecting an 85.28% upside potential from its current trading price of $15.21 to an average target of $28.18. Despite typical biotech developmental financial metrics like negative EPS, strong analyst backing and innovative approach make TRVI an attractive option for growth-seeking investors with a higher risk tolerance.
An insider at Trevi Therapeutics sold shares valued at $595,806, as reported in a recent SEC filing. The article highlights this transaction and lists other recent news concerning Trevi Therapeutics, including presentations at healthcare conferences, analyst rating adjustments, and quarterly earnings reports. Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio for chronic cough conditions.
Trevi Therapeutics is positioned to leverage its drug Haduvio to target IPF-related chronic cough, with plans to expand into non-IPF ILD and refractory chronic cough. The company's strategy focuses on concentrated pulmonology networks, enabling efficient market entry and growth. With positive Phase II data, ongoing pivotal trials, and reduced competition, TRVI presents a compelling risk/reward profile.
Walleye Capital LLC has acquired a new stake of 241,987 shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, valued at approximately $4.5 million. This investment contributes to the 95.76% institutional ownership of the company. Trevi Therapeutics maintains a "Buy" consensus rating from analysts, with a target price of $27.08, despite recent mixed analyst actions including a downgrade to "Sell" from one firm.
Trevi Therapeutics, Inc. reported wider net losses and basic loss per share in Q2 2026, alongside filing a US$149.2 million shelf registration for 8,000,000 common shares. This new financing overhang adds to existing concerns about potential dilution and weighs against the company's investment narrative, which relies on its drug Haduvio's success despite ongoing losses. Investors are urged to consider the impact of potential dilution against the drug's future commercial prospects.